The exact origins of SARS-CoV-2 are still something of a mystery, but new research may bring scientists one step closer to an explanation for how the virus reached Wuhan. Also in the episode, we dive into GEN’s coverage of the annual AACR meeting including how the community is navigating massive research budget cuts. Then we discuss a potential colorectal cancer therapy using CRISPR-edited tumor infiltrating lymphocytes and a method for delivering protein therapies and gene editors using engineered vesicles. Lastly, in business news, Recursion rethinks its pipeline, the FDA gives Abeona’s gene therapy a chance, and Bristol Myers Squibb execs open up on artificial intelligence.Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Julianna LeMieux, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base:AACR 2025: A Video Update from ChicagoBy Julianna LeMieux, PhD and Damian Doherty, GEN, April 29, 2025Hope and Headwinds at AACR in ChicagoBy Damian Doherty, GEN, April 29, 2025Senator Tammy Baldwin Supports Science in AACR SpeechBy Julianna LeMieux, PhD, GEN, April 29, 2025CRISPR-Edited TILs Fight Advanced Colorectal Cancer in PatientsBy GEN, May 4, 2025Engineered Extracellular Vesicles Could Deliver Gene Editors, Therapeutic Proteins to CellsBy GEN, April 30, 2025SARS-CoV-2 Likely Spread Through Wildlife Trade, Not Bat MigrationBy GEN, May 7, 2025Chatting with Author David Quammen about SARS-CoV-2 Will Leave You “Breathless”Originally aired: November 16, 2022Recursion Halts Four Pipeline Programs, Sharpening Cancer, Rare Disease FocusBy Alex Philippidis, GEN Edge, May 5, 2025StockWatch: Second Time’s the Charm for Abeona’s Gene TherapyBy Alex Philippidis, GEN Edge, May 4, 2025Predict First: BMS Executives Discuss Company’s AI ApproachBy Alex Philippidis, GEN Edge, March 26, 2025 Hosted on Acast. See acast.com/privacy for more information.

Ver todos los episodios